The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups

Clinical Pharmacology and Therapeutics

Volumn 69, Issue 1, 2001, Pages 24-31

  Mancinelli, Laviero M ^a,b   Frassetto, Lynda ^a,b   Floren, Leslie C ^a,b   Dressler, Dawna ^a,b   Carrier, Steve ^a,b   Bekersky, Ihor ^a,b   Benet, Leslie Z ^a,b   Christians, Uwe ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

13 O NORTACROLIMUS; CYTOCHROME P450 3A; GLYCOPROTEIN P; INTESTINE ENZYME; TACROLIMUS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MASS SPECTROMETRY; MULTICENTER STUDY; NEGRO; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VALIDATION PROCESS;

ADULT; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; MALE; TACROLIMUS;

EID: 0035133672     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.113183     Document Type: Article

References (35)

1. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A
2. Newer immunosuppressive drugs: A review
3. Tacrolimus: An update on its pharmacology and clinical efficacy in the management of organ transplantation
4. Consensus document: Therapeutic monitoring of tacrolimus (FK506)
5. Cytochrome P4503A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat
6. Metabolism of the immunosuppressant tacrolimus in the small intestine cytochrome P450, drug interactions and interindividual variability
7. Isolation, identification and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone
8. Further metabolism of FK506 (tacrolimus): Identification and biological activities of the metabolites oxidized at multiple sites of FK506
9. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients
10. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
11. Variable oral absorption of cyclosporine
12. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability
13. The adverse impact of high cyclosporine clearance rates on the incidences of acute rejection and graft loss
14. Inferior outcome of two haplotype matched renal transplants in blacks: Role of early rejection
15. Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations
16. Evidence of increased CYP3A activity in African Americans
17. Clinical trials and transethnic pharmacology
18. Influence of race ethnicity on pharmacokinetics of drugs
19. Ethnic differences in nifedipine kinetics: Comparison between Nigerians, Caucasians and South Asians
20. Inter-ethnic comparison of pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin
21. Lack of effect of race on the pharmacokinetics of irbesartan
22. Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: Ethnicity and CYP3A activity
23. Demographic considerations in tacrolimus pharmacokinetics
24. Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: Immunosuppressants
25. Good laboratory practice regulations: Final rule
26. Bioavailability of oral cyclosporine in healthy Mexican volunteers: Evidence for interethnic variability
27. CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A41B5 promoter polymorphism
28. Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?
29. Function, evolution and structure of multidrug resistance protein (MDR)
30. Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug delivery
31. Metabolism of the macrolide immunosuppressant tacrolimus by the pig mucosa in the Ussing chamber
32. Pharmacokinetics, metabolism and therapeutic drug monitoring of the macrolide immunosuppressants tacrolimus (FK506) and sirolimus (rapamycin)
33. Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver graft recipients
34. Simplified HPLC-MS assay for measurement of FK506 and its metabolites and cross validation with microparticle enzyme immunoassay (MEIA)
35. Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by HPLC-MS and microparticle immunoassay (MEIA)